Results 101 to 110 of about 46,564 (215)

BRCA2--Branching Out Too? [PDF]

JNCI Journal of the National Cancer Institute, 2015
Margaret R, Spitz, Yanhong, Liu, Christopher I, Amos   +2 more
openaire   +2 more sources

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients

Сибирский онкологический журнал, 2016
BRCA1 and BRCA2 may contribute in pancreatic cancer (PC) risk, however the selection criteria for BRCA1 testing are poorly defined. The analysis of Russian founder mutation BRCA1 5382insC in 150 PC patients identified 2 carriers.
A. A. Kashintsev, G. A. Yanus, N. Yu. Kokhanenko, V. M. Moiseenko, M. D. Hanevich, L. D. Roman, A. G. Ievleva, A. P. Sokolenko, E. N. Suspitsin, A. I. Budovskiy, A. V. Togo, N. M. Volkov, R. V. Fadeev, M. S. Dinikin, A. K. Ivanova, K. G. Shostko, E. N. Imyanitov   +16 more
doaj  

Prevalence of Novel and Recurrent Pathogenic Variants in BRCA Genes in a Cohort of Iranian Hereditary Breast Cancer Patients

Advanced Biomedical Research
Background: The incidence of breast cancer (BC) is increasing in Iranian women, especially in those with a positive family history of any type of cancer. Being a carrier of pathogenic variants in BRCA1/2 genes, significantly raises the risk of developing
Akram Sarmadi, Shaghayegh Haghjooy Javanmard, Mehrdad Zeinalian, Majid Hosseinzadeh, Mohammad Amin Tabatabaiefar   +4 more
doaj   +1 more source

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, Volume 117, Issue 5, Page 1469-1480, May 2026.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, Volume 88, Issue 6, Page 1115-1125, May 2026.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 5, May 2026.
ABSTRACT Aim Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.
Yoh Watanabe, Tsukasa Baba, Shu Soeda, Hideki Tokunaga, Wataru Yamagami, Hiroyuki Nomura, Yoichi Kobayashi, Kei Kawana, Kiyoshi Yoshino, Yoshihito Yokoyama, Hirotaka Nishi, Hiroaki Kobayashi, Yukiko Matsuzawa, Shunsuke Oyamada, Satoru Takahashi, Satoru Nagase   +15 more
wiley   +1 more source

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain ...
Carina Dumo, Faheem, Peter J. Choi, Nicholas J. Pederson, Yuge Liu, Mike Dragunow, Thomas I‐H. Park, Katharine L. Diehl, Jiney Jose   +8 more
wiley   +1 more source

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)‐cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a “BRCAness phenotype” that further ...
Kathy D. Miller, Alexandra Thomas, Sandra Althouse, Yong Zang, Erin Conder, Ryan Burgos, Bryan P. Schneider, Tarah Ballinger, Emily Douglas, Katherine Ansley, H. Josh Jang, Woonbok Chung, Jean‐Pierre Issa, Kenneth P. Nephew, Feyruz V. Rassool   +14 more
wiley   +1 more source